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Abstract 1 
 2 
Background:  Cancer results from genetic alterations that disturb the normal cooperative 3 
behavior of cells. Recent high-throughput genomic studies of cancer cells have shown that the 4 
mutational landscape of cancer is complex and that individual cancers may evolve through 5 
mutations in as many as 20 different cancer-associated genes.   6 
 7 
Methodology and Principle Findings:  We use data published by Sjöblom et al. (2006) to 8 
develop a new mathematical model for the somatic evolution of colorectal cancers. We employ 9 
the Wright-Fisher process for exploring the basic parameters of this evolutionary process and 10 
derive an analytical approximation for the expected waiting time to the cancer phenotype.  Our 11 
results highlight the relative importance of selection over both the size of the cell population at 12 
risk and the mutation rate. The model predicts that the observed genetic diversity of cancer 13 
genomes can arise under a normal mutation rate if the average selective advantage per mutation 14 
is on the order of 1%. Increased mutation rates due to genetic instability would allow even 15 
smaller selective advantages during tumorigenesis.   16 
 17 
Conclusions:  The complexity of cancer progression can be understood as the result of multiple 18 
sequential mutations, each of which has a relatively small but positive effect on net cell growth.19 
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Introduction 1 
The current view of cancer is that tumorigenesis is due to the accumulation of mutations in 2 
oncogenes, tumor suppressor genes, and genetic instability genes [1].  Sequential mutations in 3 
these genes, lead to most of the hallmarks of cancer [2]. Cancer research has benefited 4 
immensely from studies of uncommon inherited cancer syndromes that served to highlight the 5 
importance of individual genes in tumorigenesis [3]. Theoretical considerations have suggested 6 
that a handful of mutations, perhaps as few as three, may be sufficient for developing colorectal 7 
cancer [4,5].  This relatively small number is consistent with the standard model for colorectal 8 
tumorigenesis based on the identification of mutations in well-known cancer genes [6].  9 
However, Sjöblom et al. [7] have recently determined the sequence of 13,000 genes in colorectal 10 
cancers and found that individual tumors contained an average of 62 nonsynonymous mutations.  11 
Extrapolating to the entire genome, it was estimated that individual colorectal cancers contain 12 
about 100 nonsynonymous mutations and that as many as 20 of the mutated genes in individual 13 
cancers might play a causal role in the neoplastic process [7].   14 
 15 
Tumors arise from a process of replication, mutation, and selection through which a single cell 16 
acquires driver mutations which provide a fitness advantage by virtue of enhanced replication or 17 
resistance to apoptosis [8].  Each driver mutation thereby allows the mutant cell to go through a 18 
wave of clonal expansion.  Along with drivers, passenger mutations, which do not confer any 19 
fitness advantage, are frequently observed. Passenger mutations arise in advantageous clones and 20 
become frequent by hitchhiking. The accumulation of ~100 mutations per cell is therefore the 21 
result of sequential waves of clonal expansion; the observed mutations mark the history of the 22 
cancer cell, including both drivers and passengers.   23 
Beerenwinkel et al. 
Page 4 of 30 
 1 
Genetic mutations can arise either due to errors during DNA replication or from exposure to 2 
genotoxic agents. The normal mutation rate due to replication errors is in the range of 10−10 to 3 
10−9 per nucleotide per cell per division [9]. It is likely that the initial steps leading to cancer 4 
arise in cells with a normal mutation rate [10].  A normal mutation rate might also be sufficient 5 
to generate the large numbers of mutations in cancer given the many generations that the 6 
dominant cancer cell clone has gone through both before and after its initiating mutation [11,12]. 7 
However, it has also been argued that tumor cells have mutator phenotypes that accelerate the 8 
acquisition of mutations [13].   9 
 10 
Mathematical modeling of carcinogenesis has had a rich history since its introduction more than 11 
50 years ago [14,15,16]. The initial two-hit theory has evolved into more elaborate models 12 
incorporating multiple hits, rate-limiting events and genomic instability [4,17,18,19,20,21,22].  13 
Most models consider the stem cell at the base of the colonic crypt as the initial target for 14 
mutation, with the daughter cells giving rise to the adenoma and progressively increasing the risk 15 
of malignant development [4,21]. 16 
 17 
The tumor data collected by Sjöblom et al. [7] show that the mutational patterns among 18 
colorectal cancers from different patients are diverse. This observation indicates that there may 19 
be many different mutational pathways that can lead to the same cancer phenotype. In the model 20 
described below, we assume that there are 100 potential driver genes and ask for the expected 21 
waiting time until one cell has acquired mutations in a given number, up to 20, of these genes.  22 
We assume that one or two initial mutations, perhaps together with losses or gains of large 23 
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chromosomal regions [14,15], give rise to a benign tumor (adenoma) of ~1 milligram or 106 cells 1 
(Fig. 1).  We model the progression of this adenoma to full blown cancer over a period of 5 to 20 2 
years [15], in which the adenoma grows to ~1 gram, or 109 cells. Whether the whole population 3 
of cells is at risk for clonal expansion or whether a fraction of cells akin to stem cells drives 4 
growth of the adenoma is currently a subject of debate.  This is important as cancer stem cells, as 5 
well as other factors such as geometric constraints on the architecture of the adenoma, may 6 
significantly reduce the effective population size and thereby impact the waiting time to cancer 7 
[23,24]. Note that it is not size that distinguishes a cancer from an adenoma; rather it is the 8 
ability of the cancer cells to invade through the underlying basement membrane and escape from 9 
its normal anatomical position.   10 
 11 
We use the Wright-Fisher process [25] to model the somatic evolution of cancer in a colonic 12 
adenoma. We assume a cell turnover of one per day [26] and analyze the time to cancer as a 13 
function of the population size N, the per-gene mutation rate u, and the average selective 14 
advantage s per mutation. We present extensive simulation results as well as analytical 15 
approximations to the expected waiting time. The model offers a basic understanding of how the 16 
different evolutionary forces contribute to the progression of cancer. 17 
 18 
Methods 19 
Data. The collection of tumor data has been described in [7]. Briefly, ~13,000 genes were 20 
sequenced from cancers of 11 patients with advanced colorectal cancers.  Any mutant gene 21 
detected in this study was analyzed in an additional 24 patients with advanced cancers.  Tumors 22 
with mismatch repair (MMR) deficiency were not included in this cohort, as MMR is known to 23 
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increase the mutation rate by orders of magnitude and would complicate the analysis of 1 
mutations.  Mutations were found in 519 genes and of these, 105 genes were found to be mutated 2 
in at least two independent tumors.  3 
 4 
Statistical analysis. In order to test for dependencies between mutated genes, we calculated all 5 
3003 pair-wise partial correlations between the 78 genes that were considered candidate drivers. 6 
Because the number of observed tumors is much smaller than the number of genes, we used the 7 
shrinkage method introduced in [27] for estimation. 8 
 9 
Wright-Fisher process. We initially consider a colonic adenoma composed of 106 cells (~1 10 
mm
3) that is growing exponentially to reach a size of 109 cells (~1 cm3). Serial radiological 11 
observations show that the growth of unresected colonic adenomas is well approximated by an 12 
exponential function [28]. The average growth rate determined in [28] implies that it takes ~11 13 
years for an adenoma to grow from 106 to 109 cells. We consider an evolving cell population of 14 
size N(t) in generation t. Population growth is modeled by assuming that growth is proportional 15 
to the average fitness ‹w› of the population, N(t+1) – N(t) = α ‹w› N(t), where α is a constant 16 
ensuring the experimentally observed growth dynamics, and N(0) = 106. Although ‹w› changes 17 
slightly over time, the growth kinetics is still approximately exponential.  18 
 19 
Each cell is represented by its genotype, which is a binary string of length d = 100 corresponding 20 
to the 100 potential driver genes. The population is initially homogeneous and composed of wild 21 
type cells which are represented by the all-zeros string. In each generation, N(t) genotypes are 22 
sampled with replacement from the previous generation. For large population sizes of 109 cells, it 23 
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is not feasible to track the fate of each of the possible 2100 mutants in computer simulations. 1 
However, we are interested in the first appearance of any k-fold mutant in the system (k = 20). 2 
Thus, it suffices to trace the k + 1 mutant error classes, i.e., the number of j-fold mutants Nj(t) for 3 
each j = 0, …, k , in each generation. With every additional mutation we associate a selective 4 
advantage s. Thus, the relative fitness of a j-fold mutant is ∑
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where N(t) follows the above growth kinetics. 12 
 13 
We use the discrete Wright-Fisher process rather than the continuous Moran process [25], which 14 
might seem more natural for cancer progression, because the Wright-Fisher process allows for 15 
efficient computer simulations even for very large population sizes. Both models behave 16 
similarly for large population sizes [25]. 17 
 18 
Analytical approximation. The large cell population size might suggest that one could consider 19 
a replicator equation in the limit as N → ∞. However, this approach yields a Poisson distribution 20 
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for the time-dependent relative frequencies xj(t) with parameter seud st /)1( −=λ , implying that 1 
the variance of x increases over time, which contrasts with the simulation results (Fig. 3). The 2 
reason for this discrepancy is that, in the replicator equation, higher order mutants with high 3 
fitness are instantaneously generated. Thus, the time for their expansion is underestimated 4 
compared to the waiting time in the stochastic system. See supporting information for further 5 
discussion of this phenomenon.  6 
 7 
In order to account for the stochastic fluctuations in the accumulation of k mutations, we model 8 
this process by decoupling mutation and selection (see supporting information S3 for 9 
mathematical details). Briefly, we assume that j-fold mutants are generated at a constant rate 10 
with increasing j. The Gaussian describing the distribution of mutant error classes has mean vt, 11 
variance 2σ , and travels with velocity 2σsv =  (Fig. 3).  In order to determine v, we consider an 12 
(initially) exponentially growing subpopulation of j-fold mutants and calculate the expected time 13 
until one (j + 1) mutant is produced. This leads to 
2
loglog2 
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population size N, we obtain the approximation Ns
ud
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≈  for the expected time 15 
to the first appearance of any k-fold mutant. The same waiting time in a population growing 16 
exponentially from initial size )0(init NN =  to final size )(fin ktNN =  is equal to that in a 17 
constant population with effective population size fininit NNN = . Thus the speed of the mutant 18 
wave in the growing population can be approximated by the average of the values corresponding 19 
to the initial and final population sizes. This leads to )log(log fininit
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waiting time in a population growing from initN  to finN . We will often restrict our attention to 1 
constant population sizes because of the equivalent waiting time in a constant population with 2 
effective size equal to the geometric mean of the initial and final population sizes. 3 
 4 
Results 5 
The mutation data are represented in a binary matrix of size 35 × 78 whose rows correspond to 6 
35 tumor samples and whose columns correspond to the 78 candidate cancer genes identified by 7 
Sjöblom et al. [7] (Fig. 2).   A non-zero entry in cell (i, j) of this matrix indicates the presence of 8 
a mutation in gene j of tumor i. Tumors harbor between 1 and 20 mutated genes (mean = 6.5). 9 
Most of these genes (66/78 = 85%) are mutated in at most 3 different tumors resulting in highly 10 
diverse mutational patterns among the tumors. The notable exception are the three well-known 11 
cancer genes APC, p53, and K-ras which were found mutated in 24, 17, and 16 tumors, 12 
respectively. We have analyzed partial correlations between genes taking into account the small 13 
number of observations and multiple comparisons. Several pairs of genes were significantly 14 
correlated, most of them positively, but all correlations were weak and below 0.07 (Fig. S1). 15 
From this data analysis, we conclude that in colon cancer, a very small number of genes are 16 
mutated frequently and are present in many tumors. However, many other genes are involved in 17 
tumor progression, although each single gene is mutated only in a small subset of tumors without 18 
a clear pattern emerging.  19 
 20 
For the purpose of mathematical modeling of tumorigenesis, we consider the presence of an 21 
adenoma. Adenoma formation probably requires the appearance of mutations in a few genes 22 
(e.g., APC and K-ras) that are common to most tumors. We assume the occurrence of all 23 
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subsequent mutations to be independent events. When any k out of d = 100 susceptible genes are 1 
mutated in a single cell, the cancer phenotype is considered to be attained. The first cells of this 2 
type mark the onset of an invasive tumor. The Wright-Fisher process is used to describe these 3 
evolutionary dynamics. Despite the large population size of up to N = 109 cells, we can 4 
efficiently compute estimates of the time to the first appearance of any k-fold mutant by 5 
simulation, because it suffices to trace the distribution of the k + 1 mutant error classes in each 6 
generation. We assume a constant average selective advantage, s, for each mutation and a per-7 
gene mutation rate, u. Figure 3 displays the typical behavior of this process in a single 8 
simulation. After a short initial phase in which the homogeneous wild type population produces 9 
the first low-order mutants, a traveling wave is observed (Fig. 3). Apparently, this distribution of 10 
error classes has constant variance and travels with constant velocity towards higher-order 11 
mutants. Thus, we expect the time until the first k-fold mutant appears to be linear in k. This 12 
conjecture is substantiated by simulations for a wide range of parameters (Fig. S2) provided that 13 
mutations are advantageous (s > 0). 14 
 15 
Within our model, the probability of developing cancer is equated with the probability of 16 
generating at least one k-fold mutant cell in the adenoma. For k = 20, this probability as a 17 
function of time is depicted in Figure 4. The expected time to the development of cancer 18 
increases with decreasing cell population size (hence the low risk of cancer associated with very 19 
small adenomas), with decreasing selective advantage, and with decreasing mutation rate. Thus, 20 
if the population at risk is a small subset composed of actively replicating stem cells, tumor 21 
progression will be slow.  In contrast, an increased mutation rate due to genetic instability speeds 22 
up this process.  23 
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 1 
The simulations suggest that in a time frame of 5 to 15 years, cancer might develop in an 2 
adenoma of size 107 to 109 cells with a normal mutation rate of 10−7 per gene per cell division 3 
and a 1% selective advantage per mutation (Fig. 4a). Alternatively, a higher mutation rate of 10−5 4 
per gene per cell division would enable a smaller population of at-risk cells (105 to 107)  and a 5 
smaller selective advantage  (0.1%) to reach the required number of mutations in the same time 6 
interval (Fig. 4b). However, for reasonable mutation rates, a completely neutral process (s = 0) 7 
predicts waiting times that are not consistent with the observed incidence of colon cancer, as 8 
would be expected (Fig, 4, Fig. S2). 9 
 10 
Figure 5 generalizes these findings to different values of k by partitioning the parameter space of 11 
the model into regions of identical evolutionary outcomes. Each curve defines an instance of the 12 
Wright-Fisher process that results in a 10% chance of developing a k-fold mutant after 3000 13 
generations (or 8.2 years). These level curves define the parameter combinations that produce 14 
similar dynamics. For example, a small at-risk population is unlikely to generate a cancer 15 
requiring more than 10 driver gene mutations unless the selective advantage for these mutations 16 
is large (see Discussion).  17 
 18 
Based on the simulation results we have derived an analytical approximation for the expected 19 
time to cancer. The key observation is that the distribution of error types follows a Gaussian (Fig. 20 
3). This approach leads to the expression  21 
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for the expected waiting time, where k is the number of cancer-defining genes, d is the number of 1 
susceptible genes, u is the mutation rate, s the average selective advantage, and initN  and finN  2 
are the initial and final population sizes of the polyp, respectively (see Materials and Methods).  3 
The approximation is linear in k (Fig. S2) and matches closely the observed behavior of the 4 
Wright-Fisher process, as long as s > 0 (Fig. 3-5). The fit is analyzed quantitatively in the 5 
supporting information S3. The expression for tk highlights the strong effect of the selective 6 
advantage on tumorigenesis, and gives an explicit tradeoff between the evolutionary forces. 7 
 8 
Discussion 9 
Research over the past three decades has shown that cancer is an acquired genetic disorder [1]. 10 
The process of replication, mutation, and selection eventually leads to the appearance of tumors 11 
in multi-cellular organisms if they live long enough. Tumor cells accumulate many mutations in 12 
their evolutionary path [7,8,29], but not all mutations play a causal role in the evolution of the 13 
clone.  If a gene is mutated in tumors derived from different patients, it is less likely to be a 14 
passenger and more likely to provide the cell with a selective advantage to expand and dominate 15 
the population. Based on this reasoning, Sjöblom et al [7] suggested that as many as ~20 driver 16 
genes are mutated per tumor. The diverse mutational landscapes observed in tumor cells of the 17 
same tissue origin suggest that different mutations can have the same phenotypic effect. One 18 
plausible explanation for this observation is that genes are organized into intracellular pathways 19 
(signaling, metabolic, checkpoint etc) and the disturbance of these pathways drives 20 
tumorigenesis. Within each cell, every information transfer cascade requires functional proteins 21 
that are the products of distinct genes. Mutations in any one of the genes that code for proteins in 22 
a given pathway can complement each other and their genetic alterations can have similar 23 
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phenotypic effects [1]. This view is supported by the observation that multiple hits in different 1 
genes of the same pathway in individual tumors are less frequent than expected [1].  2 
 3 
In our model, we assume that each subsequent mutation has the same incremental effect on the 4 
fitness of the cell.  In general, however, the impact of a specific mutation on the phenotype of the 5 
cell will depend on the genetic background. Gene interactions, or epistasis, can be positive or 6 
negative, and they can impose constraints on the order in which mutations accumulate [1].  In 7 
this case, the model parameter s may be regarded as the average fitness increase per mutation.  In 8 
another simplifying abstraction, we have defined the tumor cell by the accumulation of 20=k  9 
mutations in different driver genes. In reality, it is unlikely that any combination of 20 genes will 10 
induce the cancer phenotype. Our assumption is based on the observed cancer genotypes which 11 
fail to reveal a striking genetic signature of cancer cells.  In this respect, our model provides 12 
lower bounds on the expected waiting time to cancer, as reaching a specific 20-fold mutant may 13 
take significantly longer.  14 
 15 
These abstractions are important because all lesions begin with a small number of neoplastic 16 
cells.  The simulations in Figure 5 show that cancers would never result from such small 17 
numbers of cells if 20 driver mutations were required and each mutation conferred only a small 18 
fitness advantage.  It is likely that some of the early mutations increase fitness more than the 19 
average, allowing a small, initiating lesion to grow into an intermediate size lesion.  Once a 20 
growth reaches this size, mutations with small fitness advantages can accumulate and eventually 21 
convert the tumor into a cancer. 22 
 23 
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The large population size of 109 cells would suggest that a purely deterministic approximation to 1 
the Wright-Fisher process is reasonable. It turns out, however, that the stochasticity associated 2 
with generating mutants of each new type has a strong impact on the evolutionary dynamics (see 3 
supporting information S3). Therefore, a deterministic model of evolutionary dynamics will 4 
significantly underestimate the time to cancer.  The closer approximation presented here exploits 5 
the regular behavior of the system of propagating a Gaussian distribution of error types and takes 6 
into account stochastic effects in determining the speed of this traveling wave. Thus, stochastic 7 
effects can play an important role even in very large populations.     8 
 9 
Tumors derived from the same tissue exhibit considerable variability in their spectrum of 10 
mutations (Fig. 2 and [7]). The number and type of mutations observed is the result of the size of 11 
the population at risk, the mutation rate, and the microenvironment of the evolving clone. The 12 
individual mutation rate can vary significantly due to genetic [29,30], and environmental effects 13 
(e.g., dietary fat intake, colonic bacterial flora, prior genotoxic therapy) [31,32]. These factors 14 
that are expected to be different for every tumor also contribute to the diversity of the mutational 15 
landscape observed in tumors.  It is also worth noting that the number of potential driver genes is 16 
likely to be an underestimate because the power of the Sjöblom et al. study to detect infrequent 17 
mutations was limited [7].  The study of larger numbers of tumors is likely to show that a few 18 
hundred different genes may function as drivers.  This increase in potential drivers, however, 19 
will not have a substantial effect on the conclusions of the models derived here (Eq. 1). 20 
 21 
Most tissues in metazoans undergo turnover and are maintained by a population of tissue specific 22 
stem cells that generally replicate at a slow rate and exhibit properties such as asymmetric 23 
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division and immortal DNA strand co-segregation [33], perhaps to minimize the acquisition and 1 
retention of mutations. Although many tumors have cancer stem cells at their root [34] and colon 2 
cancer stem cells have been reported [23,24], it is an open question whether such cells arise 3 
solely due to the progressive accumulation of mutations in normal stem cells, or because cells 4 
can re-acquire stem cell-like properties by mutation. The former scenario would suggest a much 5 
smaller effective population size, an important variable for modeling the evolution of cancer 6 
[4,21,35,36,37]. The colon has approximately 107 crypts, each one maintained by a small number 7 
of stem cells [26]. Initially, these stem cells constitute the overall population at risk, but the vast 8 
majority of patients with colon cancer develop tumors as the natural progression of mucosal 9 
adenomas [38]. Thus, adenoma formation can be regarded as a mechanism by which the 10 
population of cells at risk is increased and hence the probability of cancer in patients with 11 
multiple adenomas is dramatically increased. This is observed in familial adenomatous polyposis 12 
patients, who have inherited mutations of the APC gene. 13 
 14 
Our model permits investigation of the impact of the relevant parameters of tumor evolution on a 15 
global scale.  These parameters include the size of the population at risk, the mutation rate, and 16 
the fitness advantage conferred by specific mutations (Eq. 1). The model suggests that the 17 
average waiting time for the appearance of the tumor is strongly affected by the fitness, s, 18 
conferred by the mutations, with the average waiting time decreasing roughly as 1/s (Fig. S2). 19 
The mutation rate and the size of the population at risk contribute only logarithmically to the 20 
waiting time and hence have a weaker impact.  Thus, the model of cancer progression presented 21 
here might add to the debate whether selection [10,11] or mutation [39] is the dominant force in 22 
tumor development. 23 
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 1 
Finally, this model helps answer several questions about colorectal tumorigenesis that have long 2 
perplexed researchers and clinicians.  Why is there so much heterogeneity in the times required 3 
for tumor progression among different patients? Why is there so much heterogeneity in the sizes 4 
and development times of tumors even within individual patients, such as those with familial 5 
adenomatous polyposis, if they all have the same initiating APC mutation?  Why do cancers 6 
behave so differently with respect to their response to chemotherapeutic agents or radiation or 7 
their propensity to metastasize?  Our model is compatible with the view that a few major 8 
mutational pathways, such as those involving APC, K-ras, and p53, endow relatively large 9 
increases in fitness that can allow tumors to grow to sizes compatible with further progression 10 
(Fig. 5).  However, the final course to malignancy will be determined by multiple mutations, 11 
each with a small and distinct fitness advantage, and these mutations occur stochastically.  Every 12 
cancer will thereby be dependent on a unique complement of mutations that will determine its 13 
propensity to invade, its ability to metastasize, and its resistance to therapies.  If this model is 14 
correct, then biological heterogeneity is a direct consequence of the tumorigenic process itself. 15 
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Figure Legends 1 
 2 
Figure 1. Schematic representation of the evolution of cancer in a colonic adenoma. The 3 
adenoma grows from a population of 106 to 109 cells which accumulate mutations that drive 4 
phenotypic changes seen in cancer cells. Blue circles symbolize adenoma cells prior to 5 
accumulating the additional mutations that are the subject of modeling, green indicates cells that 6 
have acquired additional, but an insufficient number of mutations for malignancy, and red 7 
indicates cells with the number of mutations required for the cancer phenotype. 8 
 9 
Figure 2. Mutational patterns in 35 late-stage colorectal cancer tumors from Sjöblom et al. 10 
(2006). Matrix rows are indexed by tumors, columns are indexed by cancer-associated genes as 11 
identified by Sjöblom et al. (2006). Dark spots indicate mutated genes. Both tumors and genes 12 
have been sorted by an increasing number of mutations. The three genes mutated most often are 13 
APC (in 24 tumors; last column), p53 (in 17 tumors; penultimate column), and K-ras (in 16 14 
tumors; adjacent to p53 column). 15 
 16 
Figure 3. Evolution of cancer modeled by the Wright-Fisher process. The distribution of cells in 17 
the error classes N0, …, N20 is displayed in a single simulation over a time period of 12 years 18 
after which the first cell harboring 20 mutations appears. The total population size (dashed line) 19 
grows exponentially from 106 to 109 cells in this time period, Each cell has 100 susceptible 20 
genes, all of which are of wild type initially. We further assumed a mutation rate of 10−7 per 21 
gene, a 1% selective advantage per mutation, and a turnover of 1 cell division per cell per day. 22 
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Each error class has an approximately Gaussian distribution (after a short initial phase), but the 1 
introduction of each new mutant is subject to stochastic fluctuations.    2 
 3 
Figure 4. The probability of developing cancer, defined as the occurrence of a cell with any 20 4 
mutated genes out of 100. Simulation results are displayed for three different population sizes 5 
(109, solid lines; 107, dashed lines; 105, dotted lines), three different selection coefficients (10%, 6 
red lines; 1%, green lines; 0.1%, blue lines), and two different mutation rates (10-7, top; 10-5, 7 
bottom). 8 
 9 
Figure 5. Level curves of identical cancer dynamics. Each curve connects points in parameter 10 
space (x-axis: selective advantage s, y-axis: population size N) with the same evolutionary 11 
outcome, namely a 10% chance of developing a k-fold mutant after 8.2 years (or 3000 12 
generations). The mutation rate is 10−7 (solid lines) and 10−5 (dashed lines), respectively. Curves 13 
are labeled with the number k of mutated genes that defines the cancer phenotype.  14 
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Supporting information 1 
 2 
Figure S1. Histogram of 





=
2
78
3003  partial correlations between all 78 cancer-associated 3 
genes. Correlation coefficients have been computed from the 0/1 matrix displayed in Figure 2.  4 
 5 
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Figure S2. Time Tk until, in 10% of patients, k genes are mutated. The waiting time Tk (y-axis) is 1 
plotted versus the number k of mutated genes (x-axis). Left panels correspond to a normal 2 
mutation rate of u = 10−7, right panels to an increased mutation rate of u = 10−5. Population sizes 3 
of 105 (top panels), 107 (middle panels), 109 (bottom panels) are considered. The selective 4 
advantage per mutation varies among 0.1 (red lines), 0.01 (green), 0.001 (cyan), and 0 (blue). 5 
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Supporting document S3 1 
PDF document entitled “Analytical approximation for the expected waiting time” which contains 2 
the mathematical details of the model. 3 
